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To determine whether a set of functional tests, clinical scales, patient-reported questionnaires,
and specific biomarkers can be considered reliable outcome measures in patients with primary
mitochondrial myopathy (PMM), we analyzed a cohort of Italian patients.
Methods
Baseline data were collected from 118 patients with PMM, followed by centers of the Italian
network for mitochondrial diseases. We used the 6-Minute Walk Test (6MWT), Timed Up-
and-Go Test (x3) (3TUG), Five-Times Sit-To-Stand Test (5XSST), Timed Water Swallow
Test (TWST), and Test of Masticating and Swallowing Solids (TOMASS) as functional
outcome measures; the Fatigue Severity Scale and West Haven-Yale Multidimensional Pain
Inventory as patient-reported outcome measures; and FGF21, GDF15, lactate, and creatine
kinase (CK) as biomarkers.
Results
A total of 118 PMM cases were included. Functional outcome measures (6MWT, 3TUG,
5XSST, TWST, and TOMASS) and biomarkers significantly differed from healthy reference
values and controls. Moreover, functional measures correlated with patients’ perceived fatigue
and pain severity. Patients with either mitochondrial or nuclear DNA point mutations per-
formed worse in functional measures than patients harboring single deletion, even if the latter
had an earlier age at onset but similar disease duration. Both the biomarkers FGF21 andGDF15
were significantly higher in the patients compared with a matched control population; however,
there was no relation with severity of disease.
Conclusions
We characterized a large cohort of PMM by evaluating baseline mitochondrial biomarkers and
functional scales that represent potential outcome measures to monitor the efficacy of treat-
ment in clinical trials; these outcome measures will be further reinvestigated longitudinally to
define the natural history of PMM.
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Mitochondrial disorders (MDs) are the most frequent met-
abolic deficits in human pathology and have a frequency of
nuclear (nDNA) and mitochondrial DNA (mtDNA) patho-
genic variants of 1:4,300.1 Myopathy may be the initial and
isolated feature of MDs or may occur in association with other
manifestations such as deafness, polyneuropathy, ataxia,
stroke-like episodes, diabetes, and liver or kidney in-
volvement.2 As recently proposed by an international con-
sortium, “primary mitochondrial myopathies (PMM) are
genetically defined disorders leading to defects of oxidative
phosphorylation affecting predominantly, but not exclusively,
skeletal muscle”.3
The age at onset, severity, and natural history of PMM are
variable and range from serious early-onset forms with hypo-
tonia, generalized weakness, and respiratory failure to late-onset
milder forms with chronic progressive external ophthalmoplegia
as the most common phenotype of PMM in adulthood.3,4
The same consortium has identified biomarkers and a se-
ries of clinical, functional, and quality of life scales to be
applied to PMM, also in view of future pharmacologic
studies.3
The primary objective of our study was the baseline clin-
ical characterization of 118 patients with PMM using a set
of measures and biomarkers, recruited from the Nation-
wide Italian Collaborative Network of Mitochondrial
Diseases.
Methods
We prospectively collected clinical data, outcome mea-
sures, quality of life questionnaires, and biomarkers (ie,
creatine kinase [CK], lactic acid, FGF21, and GDF15) in
118 adult Italian patients with a diagnosis of PMM due to
either an mtDNA or nDNA mutation affecting oxidative
phosphorylation in mitochondria, registered in the Nation-
wide Italian Collaborative Network of Mitochondrial
Diseases. Most of the enrolled patients were taking mito-
chondrial supplements (eg, coenzyme Q10, riboflavin,
thiamine, and carnitine) at different dosages.
In a preliminary phase, a mailing list was created, and all PIs of
the network analyzed the outcome measures proposed by the
PMM experts’ consortium3; after a deep e-discussion, several
outcome measures and scales were identified:
Clinician-reported outcome measures—clinical scales
The Newcastle Mitochondrial Disease Scale for Adults
(NMDAS).
Functional tests
6-Minute Walk Test (6MWT), Timed Up-and-Go Test (x3)
3TUG, Five-Times Sit-To-Stand Test (5XSST), Timed Wa-





Fatigue Severity Scale (FSS) and West Haven-Yale Multidi-
mensional Pain Inventory (WHYMPI).
To reduce the intra- and intervariability among groups, all
investigators met once for a face-to-face meeting, in which 3
facilitators (M.M., C.L., and O.M.) performed a detailed
training on all adopted scales. Once the training had been
completed, a specific CRF was developed, and 118 consecu-
tive patients with PMM were enrolled and prospectively
studied. Subjects were studied in the morning, and at the time
of the visit, a fasting blood sample was taken for determination
of CK, lactate, GDF15, and FGF21. In some patients, blood
samples were either not collected or could not be completely
processed for technical or methodological reasons.
FGF21 and GDF15 evaluation on patient serum was per-
formed with Simple Plex cartridges using the Ella apparatus
(ProteinSimple, San Jose) according to the manufacturer’s
instructions.
Statistical analysis
Frequencies, average, median, SD, standard error, and per-
centiles were calculated for each feature. Values were reported
as mean ± SD for variables with normal distribution, as me-
dian and interquartile range (IQR) for variables with skewed
distribution, and as a percentage for categorical data. To verify
the distribution of each parameter, the Kolmogorov-Smirnov
test was performed. For continuous variables, the in-
dependent Student t test and Mann-Whitney U test were
applied to find differences between 2 groups. Differences
between results of functional tests, quality of life question-
naire scores, and laboratory values and their respective
reference values in the healthy population were evaluated
through the independent Student t test or Wilcoxon
Glossary
3TUG = Timed Up-and-Go Test (x3); 5XSST = Five-Times Sit-To-Stand Test; 6MWT = 6-Minute Walk Test; CK = creatine
kinase; FSS = Fatigue Severity Scale; IQR = interquartile range;MD = mitochondrial disorder;mtDNA = mitochondrial DNA;
NMDAS = The Newcastle Mitochondrial Disease Scale for Adults; PMM = primary mitochondrial myopathy;RC = respiratory
chain;TOMAAS = Test of Masticating and Swallowing Solids;TWST = TimedWater Swallow Test;WHYMPI =West Haven-
Yale Multidimensional Pain Inventory.
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signed-rank test; reference values were derived from the
literature.5–12 Continuous and categorical data were corre-
lated through the Pearson correlation test or Spearman rank
correlation test, according to the distribution of each param-
eter. To identify predictors of NMDAS results and quality of
life questionnaire scores, univariate and multivariable logistic
regression analysis was performed. Before performing partial
correlations and regression analysis, variables with a skewed
distribution were logarithmically corrected. Differences
among patients harboring mtDNA mutation, mtDNA single
deletion, and nDNA mutation were evaluated using analysis
of variance one-way and Bonferroni post hoc tests for data
with normal distribution and Kruskal-Wallis and Dunn-
Bonferroni post hoc tests for data with skewed distribution,
after assessing the equality of variances for each variable using
parametric and nonparametric Levene tests. A similar analysis
was conducted by dividing the patients into those with de-
fective mitochondrial translation machinery, with mtDNA
deletions, and with defects in respiratory chain (RC)
subunits/assembly factors. For analysis on TOMASS scores
among patients harboring different mutation types, theMann-
Whitney U test was performed between all pairs of groups
because variances resulted heterogeneous, and values were
skewed distributed. In all cases, a p value of less than 0.05 was
regarded as significant; a lower value was indicated if it was
found. Biostatistical analysis was performed with IBM SPSS
20.0.0 program.
Data availability
Current article data are accessible from Michelangelo
Mancuso, University of Pisa. In accordance with the data
protection legislation in Europe (General Data Protection
Regulation), to share the data of the Italian Network, it is
necessary to stipulate an agreement between the Univer-
sity of Pisa and the applicant institution. Study data
can be requested by contacting Michelangelo Mancuso
(michelangelo.mancuso@unipi.it).
Standard protocol approvals, registrations,
and patient consents
Written informed consent was obtained from all participants,
and the ethics committees of each center approved the study.
Results
A total of 118 PMM cases were enrolled (50 men), with mean
age 50.62 ± 12.6 years, disease onset 31.40 ± 14.7 years, and
disease duration 21.5 ± 12.3 years.
Table 1 shows the whole data set as mean ± SD or median and
IQR, according to the distribution of each value (normal or
skewed distribution). Functional test results (6MWT, 3TUG,
5XSST, TWST, and TOMASS) and questionnaire results
(FSS and WHYMPI) were compared with the respective
normal values, differentiated by sex for the TOMASS and
considering the lower limit of normality for FEV1.
Forty-six patients (39%) harbored an mtDNA point muta-
tion, 31 (26.3%) a nuclear gene mutation, and 41 (34.7%) an
mtDNA single deletion. Genotypes are shown in supple-
mentary table 1, links.lww.com/NXG/A325, categorized as
done by Lethonen13 into defective mitochondrial translation
machinery, mtDNA deletions, and defects of RC subunits/
assembly factors. In 12 patients with mtDNA multiple dele-
tions, at the time of the submission, WES is still ongoing
(already tested for mtDNA point mutations, POLG, ANT1,
Twinkle, and OPA1). Heteroplasmy levels, available from
muscle specimens in 40 patients (46%), were not significantly
different between mtDNA point mutation and single deletion
groups. Heteroplasmy levels obtained in other tissues (blood
or urine sediment) were not considered to reduce bias in
statistic comparisons.
We observed a significant difference for the 6MWT (p <
0.001, figure 1A), 3TUG (p < 0.01, figure 1B), 5XSST (p <
0.001, figure 1C), TOMASS (only in female p < 0.05, figure
1D), and FSS (p < 0.01, figure 1E) compared with normative
values. FEV1 resulted in the range of normality (table 1).
The WHYMPI gives an overall estimation of the pain expe-
rience, taking into account cognitive and behavioral factors,
with a direct correlation between the WHYMPI score and the
severity of pain. The 52 WHYMPI items are divided into 3
sections, with part I subitems evaluating pain severity. PMM
cases showed high scores for pain severity even when com-
pared with the 120 chronic pain cohort data by Kerns et al.11
(table 1), in which most patients (81.5%) were male (vs 42%
of our cohort) but with the same mean age at the evaluation
(50.8 vs 50.6 years of our study).
Both exploratory mitochondrial biomarkers FGF21 and
GDF15, available in 80 patients, were significantly higher (p <
0.001) when compared with a matched control population
(table 2 and figure 2). On the contrary, blood lactate at rest
and CK did not significantly differ between patients with
PMM and healthy controls; however, lactate was higher than
1.8 mMol/L in 54.3% of patients (and above 2 mMol/L in
30.5%), and CK values were slightly altered in 34.4% of men
and 33.3% of women. Blood biomarkers were not correlated
with genotypes, disease duration, FSS, NMDAS, and TWST.
Exploratory biomarkers were not significantly different be-
tween male and female patients. CK showed a trend toward
statistical significance (p = 0.059), being higher in men.
Heteroplasmy levels in muscle did not correlate with clinical
features or functional tests or scale severity. Figure 3 shows, as
an example, the relationship between the 6MWT and the most
common mtDNA genotypes in our cohort; the same is ob-
servedwith all other parameters (data not shown). Similarly, no
differences were observed comparing heteroplasmy levels be-
tween the mtDNA mutation and single deletion groups and
functional tests or scales. A subanalysis was conducted on the
20 m.3243A>G patients; lactate was elevated in 40% of these
patients. Mitochondrial biomarkers (FGF21 andGDF15) were
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available in 15/20; in this subset of patients, lactate levels (but
not CK) correlated with FGF21, GDF15, FEV1, and hetero-
plasmy levels, but not with functional test scores.
We also evaluated the differences among the PMM geno-
types (mtDNA mutation, mtDNA single deletion, and
nDNA mutation). Patients harboring single deletions per-
formed significantly better than others in the 6MWT,
3TUG, and 5XSST and had an earlier age at onset. However,
they showed the worst results in the TOMASS and FEV1.
The mtDNA and nDNA mutant patients did not differ sig-
nificantly on functional scales and showed worst perfor-
mances than single deletion (supplementary table 2, links.
lww.com/NXG/A325).
Moreover, a bivariate analysis showed a direct correlation
between the 6MWT and males, between FEV1 and females,
NMDAS and disease duration (table 3). The observed dif-
ferences in pain severity between males and females could be
an expression of hormonal factors6; no difference was ob-
served in biomarker levels.
A correlation analysis among the functional scales was also
conducted. It revealed an indirect correlation between the
6MWT and FSS, between the 6MWT and NMDAS, and a
direct correlation between 3TUG and TWST and FSS and
NMDAS scores (Supplementary table 3, links.lww.com/
NXG/A325). According to the relations observed among
gender, mutation type, disease duration and clinical, func-
tional tests, and QoL questionnaires scores, we performed a
correlation and multivariate regression analysis, including
gender, mutation type, and duration of disease as independent
variables. This multivariate analysis model confirmed the re-
lation between functional scales andNMDAS and FSS results,
regardless of the other features of patients (Supplementary
table 4, links.lww.com/NXG/A325). Therefore, FSS in-
directly correlates with the 6MWT and directly with the other
scales, thus revealing an agreement between the fatigue
Table 1 Clinical features and characterization of functional outcome measures of our cohort
No. (of 118 patients) Value Normal value p Value
Male 50 42.4%
Female 68 57.6%
Patients with mDNA mutation 46 39%
Patients with nDNA mutation 31 26.3%
Patients with single deletion 41 34.7
Heteroplasmy levels 40 (of 87) 53.97 ± 20.6
Age at onset (y) 118 31.4 ± 14.8
Current age (y) 118 50.6 ± 12.5
Disease duration (y) 105 21.5 ± 12.3
BMI 85 23.5 ± 6 18.5–24.9 n.s.
6MWT (meters) 116 Male, 420 (382.4–447.8)
Female, 366 (303.8–426)
Male, 638 ± 44
Female, 593 ± 57
<0.001
<0.001
3TUG (s) 114 28.8 (19–37.33) 8 <0.01






5XSST (s) 117 20.6 ± 13 <11.4 <0.001
TWST (ml/sec) 103 8.7 (7–14) <10 n.s.
FSS 116 39.5 ± 14.7 <2.3 <0.01
WHYMPI (pain severity) 111 2.37 ± 1.64 3.55a n.s.
NMDAS 118 18.5 ± 10.5
FEV1 (%) 56 84.9 ± 15.6 ≥80 n.s.
Abbreviations: 3TUG = Timed Up-and-Go Test (x3); 5XSST = Five-Times Sit-To-Stand Test; 6MWT = 6-Minute Walk Test; FSS = Fatigue Severity Scale; n.s. = not
significant; TWST = Timed Water Swallow Test; TOMAAS = Test of Masticating and Swallowing Solids; WHYMPI = West Haven-Yale Multidimensional Pain
Inventory.
Data are expressed as mean ± SD for variables with normal distribution, as median and interquartile range for variables with skewed distribution, and in
comparison with normal value.
a Normative data of the chronic pain cohort data (N = 120) by Kerns et al. 1985.
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perceived by the patient and the objective motor functional
scales. Finally, a correlation between the NMDAS and the
motor functional scales was observed.
Patients were also analyzed by considering the subgroups identi-
fied by Lethonen (supplementary table 4, links.lww.com/NXG/
A325).13 Among these subgroups, there were no statistically sig-
nificant differences in clinical features, functional tests, or bio-
markers, except for RC subunit–mutated patients (only 3 patients,
no statistical power) who showed an earlier age at onset and
higher pain severity. The only RC-mutated patient with explor-
atory biomarker available showed low FGF21 and GDF15 values.
Bivariate correlation among mitochondrial biomarkers, QoL
questionnaires, functional tests, NMDAS, and FEV1 were
conducted separately in the subgroups according to Lethonen
(supplementary table 5, links.lww.com/NXG/A325), exclud-
ing the RC-mutated patients because poorly represented. In
mitochondrial translationmachinery–mutated patients, FGF21
andGDF15 values directly correlated with heteroplasmy levels,
and GDF15 and lactate directly correlated with NMDAS. In
mtDNA deletions, GDF15 directly correlated with lactate.
Discussion
We report a cohort study describing the baseline features of
118 adult patients with PMM, in which several outcome
measures suggested by the International Consortium3 were
assessed.
Figure 1 Results
(A–D) Composite figure showing functional test results. (A): 6MWT values inmales and females; (B): 3TUG result distribution; (C): 5XSST result distribution; (D):
TOMASS result distribution; (E): FSS result distribution. 3TUG = Timed Up-and-Go Test (x3); 5XSST = Five-Times Sit-To-Stand Test; 6MWT = 6-MinuteWalk Test;
FSS = Fatigue Severity Scale; TOMASS = Test of Masticating and Swallowing Solids.
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Data about 6MWT results in our cohort were compared with
the ones presented in the studies of Karaa et al.14 and Madsen
et al.15 Although we observed similar results in the 6MWT
between our cohort and the MOTOR study,15 a significant
difference (p < 0.01) between our 6MWT values and the ones
in MMPOWER14 was observed. A possible explanation could
be that MMPOWER enrolled more females (83%) compared
with MOTOR (58%) and our study (57.6%).
FGF21 and GDF15 levels were significantly altered compared
with the healthy control group. Although we did not find any
difference in FGF21 levels between PMM genotypes, we
confirm the role of FGF21 as a reliable serum marker in
mitochondrial disease diagnostics, whereas lactate and CK
levels are not. In the subgroup with defective mitochondrial
translation machinery, FGF21 and GDF15 directly correlated
with heteroplasmy levels and disease severity as valued by
NMDAS.
It is notable that there were no significant differences of CK and
lactate levels between patients with PMM and normal values,
whereas there were for FGF21 and GDF15. We confirm that
normal CK and lactate values, being altered only in a small
portion of patients with specific genotypes, do not exclude the
diagnosis of PMM as well as other metabolic myopathies.1,16
Clinically, this could be very helpful in general neurologic
settings—where these patients are likely to complain of pain,
myalgia, cramps, reduced exercise tolerance, common and
nonspecific complaints in PMM. In this context, CK and
lactate screening could lead to a false-negative diagnosis of
PMM, whereas FGF21 and GDF15 do not. However, CK and
lactate still play an important role in the patient’s follow-up,
especially in those cases associated with lactic acidosis or
rhabdomyolysis.
GDF15 was also elevated in our patients, but a wide variety of
other neuromuscular diseases of nonmitochondrial origin
(such as muscular dystrophy or spinal muscular atrophy) can
induce high GDF15 levels; indeed, GDF15 has higher sensi-
tivity but lower specificity.17–19 Measurement of FGF21 and
GDF15 concentrations in serum might be useful as a first-line
diagnostic tool for PMM, whereas their role as a potential
biomarker for therapeutic efficacy in future trials is still un-
clear. In a recent trial involving deoxynucleoside therapy in
thymidine kinase 2–mutated PMM, Domı́nguez-González
et al.20 promisingly showed a significant decrease in GDF15
levels after treatment. Additional data and longitudinal studies
are required to validate their utility in clinical trials and to
determine whether they can be used as proof of clinical effi-
cacy of a treatment.
Figure 2 FGF21 and GDF15 values in patients and controls
Table 2 Biomarkers in patients and comparison with normal value and controls
No. (of 118 patients) Value Normal value Value in the control group p Value
FGF21 (pg/mL) 80 509.6 (332.5–788.9) 88.4 (51.1–2 10.2)
n° samples = 103
<0.001
GDF15 (pg/mL) 80 2473,7 (1596,1–3884,9) 767.5 ± 434 (n° samples = 59) <0.001
CK (IU/L) 99 Male: 208 (133.8–399)





Lactate (mMol/L) 99 1.7 (1.1–2.5) 2 n.s.
Abbreviation: n.s. = not significant.
Data are expressed as mean ± SD for variables with normal distribution, as median and interquartile range for variables with skewed distribution.
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The functional tests and scales adopted here were impaired in
PMM. This confirms that they could represent useful tools to
monitor disease status and also play a potential role as out-
come measures to evaluate the effectiveness of drugs in up-
coming clinical trials. Moreover, the functional scales showed
a strong agreement with the perceived fatigue evaluated with
the FSS and pain severity assessed by the WHYMPI. There-
fore, they represent good, reliable, and easily assessable
measures of fatigue, pain, and exercise intolerance, common
symptoms and complaints of PMM that are often difficult to
measure in clinical practice.4
The 6MWT is a well-validated outcome measure for a large
group of neuromuscular diseases and is also used to monitor
the natural history and the efficacy of treatments.21–23 Con-
sistently, the 6MWT is a good measure of motor impairment
in PMM, which correlates with the perceived exercise in-
tolerance, pain severity, and fatigue. However, in view of fu-
ture therapeutic trials, there are no data on the 6MWT decline
over time in PMM. Thus, longitudinal observational studies
are strongly needed in PMM.
The 3TUG is noninvasive and easy to perform in daily
practice and provides a quick score of pelvic girdle weakness
and fatigue; it has recently been tested in Lambert-Eaton
myasthenia and is sensitive to 3,4-diaminopyridine therapy.24
The 3TUG and 5XSST in our cohort were significantly ele-
vated, and the 3TUG correlated well with fatigue and pain
severity.
Furthermore, an indirect correlation was found between the
NMDAS score and functional performance (6MWT, 3TUG,
and TWST), thus confirming the role of NMDAS as the
referred scale for clinic evaluation also in PMM. The corre-
lation between the NMDAS score and disease duration seems
to suggest a worse clinical phenotype in patients with earlier
diagnosis.
Patients with different mutations also performed differently in
functional scales, whereas genotype did not influence disease
duration and NMDAS scores. Single deletion, with an earlier
age at onset, seemed to perform better in the 6MWT, 3TUG,
and 5XSST, but had a worse score result in the TOMASS and
FEV1, whereas mtDNA point mutations and nDNA-mutated
patients showed worse results in the 6MWT, 3TUG, and
5XSST. Of interest, heteroplasmy did not correlate with
functional tests or scales. However, heteroplasmy levels were
available only in half of our mtDNA-related population, and
this lack of correlation should be further explored in addi-
tional and even larger cohorts. In m.3243A>G patients, al-
though we have found a significant correlation between
lactate and FGF21, GDF15, FEV1, and heteroplasmy levels,
Figure 3 Correlation between heteroplasmy levels and 6MWT results
6MWT = 6-Minute Walk Test.
Table 3 Bivariate correlation among sex, mutation type,
and disease duration and QoL questionnaires,
functional tests, NMDAS, and FEV1
Bivariate correlation between
demographic features and functional
tests, QoL questionnaires, and NMDAS
Coefficient p Value
Female and WHYMPI pain
severity scores
0.257 <0.01
Male and 6MWT results 0.291 <0.01




Abbreviations: 6MWT = 6-Minute Walk Test; WHYMPI = West Haven-Yale
Multidimensional Pain Inventory.
In all cases, a p value of less than 0.05 was considered significant; a lower
value is indicated if it was found.Only statistically significant data are shown.
Neurology.org/NG Neurology: Genetics | Volume 6, Number 6 | December 2020 7
we failed to confirm the correlation between heteroplasmy
levels and disease severity, as found in the UK population.25
FSS and WHIMPI appeared skewed toward the female
gender, without any significant difference in FGF21 or
GDF15. This could be due to hormonal factors or difference
in muscle mass because CK and BMI showed higher values
in males.16,26
Swallowing impairment is frequently observed in PMM,27,28
in about 15% of Italian patients with PEO,27 with females
being affected more, probably because of more severe
weakness, as already reported.29 Dysphagia also seems to be
a prominent feature in single deletion patients; compared
with other genotypes, we found significant worst scores in
the swallowing scale in single deletion patients, thus con-
firming that dysphagia is a canonical feature of this
disorder.30,31
Therefore, we confirm the need for a periodic phoniatric as-
sessment of swallowing, considering the disease burden,
morbidity, and mortality associated with ab ingestis pneu-
monia. FEV1 in our cohort tended to the upper than the lower
level of normality. However, it would be advisable to reeval-
uate the spirometry of these patients over time because pa-
tients with PMMmay develop respiratory failure, and it is not
known how and with what severity it manifests over time.
Although we did not find any significant alteration in the
respiratory measure, we stress the necessity of periodic eval-
uation of pulmonary function tests and spirometry.
Our study has some limitations. We have enrolled patients at
different stages of disease, and the timing of the biomarkers
analysis and of the clinical analysis was variable from patient to
patient, and some subset of outcome measures selected are
not available for all 118 participants. In 12 patients with
mtDNA multiple deletions, the nuclear defect is still un-
known; however, we believe that this does not affect the main
conclusions of our study. Moreover, functional outcomes are
highly dependent on the skill of the investigator and very
sensitive to interindividual variance. To reduce the inter-intra
variability, training sessions were organized before the study,
and the same investigators were involved in all measurements.
In addition, we did not collect control values—beside FGF21
and GDF15—but we have referred to normative values where
N size, sex, and age distribution of the control data may be not
clearly stated. However, our final goal was to obtain a clear
picture of basal values in PMM as a starting baseline in view of
natural history studies and clinical trials. Finally, we have
collected these cross-sectional data at time 0, but it is crucial to
also monitor them during the natural history of the PMM
(follow-up is ongoing at our centers).
We characterized a large cohort of patients with PMM,
providing baseline data on a functional scale that could be
reliable functional outcome measures in future PMM clinical
trials (6MWT, 3TUG, 5XSST, TWST, and TOMASS).
Functional test results fit well with perceived fatigue and
pain, and elevated FGF21 and GDF15 distinguished patients
with PMM from healthy controls. Further investigations,
evaluating the longitudinal evolution of this outcome mea-
sures over time, are strongly needed and planned to un-
derstand PMM natural history to quantify the impact of
disease-modifying therapies.
Study funding
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20. Domı́nguez-González C, Madruga-Garrido M, Mavillard F, et al. Deoxynucleoside

























Cattolica del Sacro Cuore,
Roma, Italy












































Cattolica del Sacro Cuore,
Roma, Italy

























































Department of Clinical and
Experimental Medicine,
Neurological Clinic,
University of Pisa, Italy






Department of Clinical and
Experimental Medicine,
Neurological Clinic,
University of Pisa, Italy
Designed and
conceptualized the study,
interpreted the data, and
revised the manuscript
for intellectual content
Neurology.org/NG Neurology: Genetics | Volume 6, Number 6 | December 2020 9
21. Takeuchi Y, Katsuno M, Banno H, et al. Walking capacity evaluated by the 6-minute
walk test in spinal and bulbar muscular atrophy. Muscle and Nerve 2008;38:964–971.
22. Mcdonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other
endpoints in Duchenne muscular dystrophy: longitudinal natural history observations
over 48 weeks from a multicenter study. Muscle and Nerve 2013;48:343–356.
23. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase
alfa in late-onset Pompe’s disease. N Engl J Med 2010;362:1396–1406.
24. Sanders DB, Juel VC, Harati Y, et al. 3,4-diaminopyridine base effectively treats the
weakness of Lambert-Eaton myasthenia. Muscle and Nerve 2018;57:561–568.
25. Grady JP, Pickett SJ, Ng YS, et al. Mt DNA heteroplasmy level and copy number indicate
disease burden in m.3243A>G mitochondrial disease . EMBO Mol Med 2018;10:e8262.
26. Vincent K, Tracey I. Hormones and their Interaction with the pain experience. Rev
Pain 2008;2:20–24.
27. Mancuso M, Orsucci D, Angelini C, et al. Redefining phenotypes associated with
mitochondrial DNA single deletion. J Neurol 2015;262:1301–1309.
28. Smits BW, Heijdra YF, Cuppen FWA, van Engelen BGM. Nature and frequency of
respiratory involvement in chronic progressive external ophthalmoplegia. J Neurol
2011;258:2020–2025.
29. Heighton JN, Brady LI, Newman MC, Tarnopolsky MA. Clinical and demographic
features of chronic progressive external ophthalmoplegia in a large adult-onset cohort.
Mitochondrion 2019;44:15–19.
30. Pfeffer G, Sirrs S, Wad NK, Mezei MM. Multisystem disorder in late-onset chronic
progressive external ophthalmoplegia. Can J Neurol Sci 2011;38:119–123.
31. Hedermann G, Løkken N, Dahlqvist JR, Vissing J. Dysphagia is prevalent in patients
with CPEO and single, large-scale deletions in mtDNA. Mitochondrion 2017;32:
27–30.
10 Neurology: Genetics | Volume 6, Number 6 | December 2020 Neurology.org/NG
DOI 10.1212/NXG.0000000000000519
2020;6; Neurol Genet 
Vincenzo Montano, Francesco Gruosso, Valerio Carelli, et al. 
from Italy
Primary mitochondrial myopathy: Clinical features and outcome measures in 118 cases




including high resolution figures, can be found at:
References
 http://ng.neurology.org/content/6/6/e519.full.html##ref-list-1











its entirety can be found online at:




Information about ordering reprints can be found online:
reserved. Online ISSN: 2376-7839.
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights
an open-access, online-only, continuous publication journal. Copyright Copyright © 2020 The Author(s). 
is an official journal of the American Academy of Neurology. Published since April 2015, it isNeurol Genet 
